The Profound Impacts of Precision Medicine, Genomic Sequencing on Cancer Care
Precision Oncology is helping NCI treat cancer based on specific genetic changes in a patient’s tumor by allowing them to target mutations that will lower toxicity and improve overall effectiveness of the treatment.
A clinical trial at the National Cancer Institute called NCI-MATCH showed how cancer patients could benefit from genomic sequencing and is now informing future trials on precision medicine.
The NCI Molecular Analysis for Therapy Choice Trial initially screened 6,000 patients and treated 1,300 of them by pairing certain medications with their specific tumors regardless of the cancer type. Future trials like ComboMATCH will now look at precision medicine to study how tumors respond to targeted treatments.
NCI Researchers Dr. Lindsay Harris and Dr. Peter O’Dwyer shared how precision oncology is expanding treatment options and increasing patients’ survival rates. They also discuss the importance of clinical trials like these for progressing the fight against cancer.
-
Dr. Lyndsay Harris Associate Director, Cancer Diagnosis Program NCI -
Dr. Peter O'Dwyer Group Co-Chair ECOG-ACRIN Cancer Research Group
-
Navy CTO on the Service’s AI-First Push
The service is focused on increasing speed and scale for software development and AI.
7m watch -
Readiness Lessons From CIA's First Chief Wellbeing Officer
Former CIA Chief Wellbeing Officer Jennifer Posa discussed why workforce wellbeing is a strategic driver of mission success.
42m watch -
Air Force Software Official: AI Should Reuse Code, Not Rewrite It
CTO Kurt Jarvis explained how RAG, vector databases and DevSecOps guardrails help agencies safely integrate AI into coding.
7m watch -
Army Targets New DevSecOps Initiative to Speed Code Reviews
Gabe Chiulli said ‘Project Gatekeeper’ will use AI-assisted code evaluation and faster deployment authorizations.
8m watch
